Semaglutide in NASH-related cirrhosis: still a long way to go? – Authors' reply

Rohit Loomba; Philip N. Newsome

doi:10.1016/S2468-1253(23)00160-7

Semaglutide in NASH-related cirrhosis: still a long way to go? – Authors' reply

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	694-695
Number of pages	2
Journal	The Lancet Gastroenterology and Hepatology
Volume	8
Issue number	8
Early online date	12 Jul 2023
DOIs	https://doi.org/10.1016/S2468-1253(23)00160-7
Publication status	Published - Aug 2023

Bibliographical note

Funding:
RL and PNN were investigators in the trial and received grants from the study sponsor paid to their institutions to conduct the study. RL is co-founder of LipoNexus Inc, and a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen, Madrigal, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89bio, Terns Pharmaceuticals, and Viking Therapeutics. In addition, his institutions have received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes, and Terns Pharmaceuticals. PNN has received grants from Novo Nordisk and Boehringer Ingelheim; and has acted as a consultant on behalf of the University of Birmingham for Novo Nordisk, Boehringer Ingelheim, Gilead, Intercept Pharmaceuticals, Pfizer, and Poxel Pharmaceuticals.

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/S2468-1253(23)00160-7Licence: None: All rights reserved

Cite this

@article{4a6279a38f1c47d59317bf31a86f7423,

title = "Semaglutide in NASH-related cirrhosis: still a long way to go? – Authors' reply",

author = "Rohit Loomba and Newsome, {Philip N.}",

note = "Funding: RL and PNN were investigators in the trial and received grants from the study sponsor paid to their institutions to conduct the study. RL is co-founder of LipoNexus Inc, and a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen, Madrigal, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89bio, Terns Pharmaceuticals, and Viking Therapeutics. In addition, his institutions have received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes, and Terns Pharmaceuticals. PNN has received grants from Novo Nordisk and Boehringer Ingelheim; and has acted as a consultant on behalf of the University of Birmingham for Novo Nordisk, Boehringer Ingelheim, Gilead, Intercept Pharmaceuticals, Pfizer, and Poxel Pharmaceuticals.",

year = "2023",

month = aug,

doi = "10.1016/S2468-1253(23)00160-7",

language = "English",

volume = "8",

pages = "694--695",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Semaglutide in NASH-related cirrhosis

T2 - still a long way to go? – Authors' reply

AU - Loomba, Rohit

AU - Newsome, Philip N.

N1 - Funding: RL and PNN were investigators in the trial and received grants from the study sponsor paid to their institutions to conduct the study. RL is co-founder of LipoNexus Inc, and a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen, Madrigal, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89bio, Terns Pharmaceuticals, and Viking Therapeutics. In addition, his institutions have received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes, and Terns Pharmaceuticals. PNN has received grants from Novo Nordisk and Boehringer Ingelheim; and has acted as a consultant on behalf of the University of Birmingham for Novo Nordisk, Boehringer Ingelheim, Gilead, Intercept Pharmaceuticals, Pfizer, and Poxel Pharmaceuticals.

PY - 2023/8

Y1 - 2023/8

UR - http://www.scopus.com/inward/record.url?scp=85164470471&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(23)00160-7

DO - 10.1016/S2468-1253(23)00160-7

M3 - Comment/debate

C2 - 37453429

AN - SCOPUS:85164470471

SN - 2468-1253

VL - 8

SP - 694

EP - 695

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 8

ER -